Carboplatin and Paclitaxel with Pertuzumab and Trastuzumab or Bevacizumab in Treating Patients with Breast Cancer

Inclusion Criteria

• Histologically proven unilateral or bilateral primary breast carcinoma; (in case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint)
• Tumor size is clinically at least 1 cm in greatest diameter (palpable or by imaging) and/or with involved lymph node; in case of inflammatory disease, the extent of inflammation may be the measurable lesion
• Documentation of inflammatory breast cancer
• Performance status of 0-2 by Eastern Cooperative Oncology Group (ECOG) criteria
• Known HER2 status
• Normal cardiac function must be documented within 90 days prior to registration either via an echocardiogram (ECHO) or multigated acquisition scan (MUGA) or per physician’s review of symptoms and medical history; if an ECHO is performed as standard of care, the ejection fraction must be above the normal limit of the institution; if not available in the medical chart, the ECHOs or MUGAs are not required to be repeated for research purposes
• Staging work-up prior to registration
• Absolute neutrophil count (ANC) >= 1,500/ul
• Platelets >= 100,000/ul
• Total bilirubin < 1 x upper limit of normal (ULN)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN
• Creatinine < 1.5 x ULN
• Random urine total protein < 100 mg/dL. Urine protein creatinine (UPC) ratio < 2 g (bevacizumab patients only)
• Negative pregnancy test for women of childbearing potential within 14 days prior to registration
• All patients must be informed of the investigational nature of this study and must sign and\ give written informed consent in accordance with institutional and federal guidelines

Exclusion Criteria

• Evidence of distant metastasis; if radiographic suspicion of distant metastatic site, a negative biopsy must be available in the medical record. If not available in the medical record, the subject may be included and a confirmatory biopsy is not required to be performed for research purposes
• Known or suspected congestive heart failure, angina pectoris requiring antianginal medication, or other clinically significant cardiac condition
• Pregnant or nursing women may not participate; women of childbearing potential may not participate unless they have agreed to use an adequate contraceptive method throughout study treatment and for one month after completion of treatment
• Male patients
• Pre-existing peripheral neuropathy of severity grade >= 2 (limiting instrumental activities of daily living)
• Incomplete wound healing
• Active and significant bleeding
• Known allergy, hypersensitivity or prior infusion reaction to one or more of the therapies incorporated into this treatment protocol
• Bone marrow depression or hematologic parameters in the range that would increase the risk for severe bleeding